The estimated Net Worth of Shalini Sharp is at least $10.3 Million dollars as of 17 May 2024. Ms. Sharp owns over 2,100 units of Sutro Biopharma Inc stock worth over $9,681 and over the last 18 years she sold STRO stock worth over $10,166,836. In addition, she makes $129,180 as Independent Director at Sutro Biopharma Inc.
Shalini has made over 38 trades of the Sutro Biopharma Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently she exercised 2,100 units of STRO stock worth $9,681 on 17 May 2024.
The largest trade she's ever made was exercising 31,843 units of Sutro Biopharma Inc stock on 16 September 2019 worth over $176,410. On average, Shalini trades about 2,362 units every 35 days since 2007. As of 17 May 2024 she still owns at least 2,100 units of Sutro Biopharma Inc stock.
You can see the complete history of Ms. Sharp stock trades at the bottom of the page.
Shalini Sharp is an Independent Director of the Company. Since May 2012, Ms. Sharp has served as Chief Financial Officer and Executive Vice President for Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of therapies for rare genetic diseases. Prior to Ultragenyx, Ms. Sharp served as Chief Financial Officer of Agenus Inc., a publicly traded biotechnology company focused on cancer immunotherapies, from 2006 to 2012, and from 2003 to 2006 held increasing roles of responsibility at Agenus spanning strategic planning, corporate development, investor relations, corporate finance and business development. Prior to Agenus, Ms. Sharp held similar roles at Elan Pharmaceuticals, Inc., including serving as chief of staff to the chair of the board of directors during that company’s restructuring. Ms. Sharp also previously served as a management consultant at McKinsey & Company as well as an investment banker at Goldman Sachs, specializing in pharmaceuticals and medical devices. Ms. Sharp currently serves on the board of directors of Precision Biosciences as well as on the board of directors of the TB Alliance, a non-profit organization dedicated to the development and distribution of treatments for tuberculosis in the developing world. Ms. Sharp previously served on the boards of directors of Array Biopharma Inc. and Agenus. Ms. Sharp received a B.A. in English literature from Harvard College and an M.B.A. from Harvard Business School.
As the Independent Director of Sutro Biopharma Inc, the total compensation of Shalini Sharp at Sutro Biopharma Inc is $129,180. There are 9 executives at Sutro Biopharma Inc getting paid more, with William Newell having the highest compensation of $3,817,120.
Shalini Sharp is 43, she's been the Independent Director of Sutro Biopharma Inc since 2018. There are 21 older and no younger executives at Sutro Biopharma Inc. The oldest executive at Sutro Biopharma Inc is Dr. Shabbir T. Anik, 68, who is the Chief Technical Operations Officer.
Shalini's mailing address filed with the SEC is 12780 EL CAMINO REAL, , SAN DIEGO, CA, 92130.
Over the last 6 years, insiders at Sutro Biopharma Inc have traded over $14,451,171 worth of Sutro Biopharma Inc stock and bought 750,858 units worth $10,652,478 . The most active insiders traders include Corp /De/ Celgene, John Gordon Freund, and Daniel Janney. On average, Sutro Biopharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $129,762. The most recent stock trade was executed by Jane Chung on 9 August 2024, trading 18,750 units of STRO stock currently worth $86,438.
at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll
Sutro Biopharma Inc executives and other stock owners filed with the SEC include: